The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial
Open accessAbstract
Importance: Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified FOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal adenocarcinoma; mature data are now available. Objective: To report 5-year outcomes and explore prognostic factors for overall survival. Design, Setting, and Participants: This open-label, phase 3 randomized clinical trial was conducted at 77 hospitals in France and Canada and included patients aged 18 to 79 years with histologically confirmed pancreatic ductal adenocarcinoma who had undergone complete macroscopic (R0/R1) resection within 3 to 12 weeks before randomization. Patients were included from April 16, 2012, through October 3, 2016. The cutoff date for this analysis was June 28, 2021. Interventions: A total of 493 patients were randomized (1:1) to receive treatment with modified FOLFIRINOX (oxaliplatin, 85 mg/m 2 of body surface area; irinotecan, 150-180 mg/m 2; leucovorin, 400 mg/m 2; and fluorouracil, 2400 mg/m 2, every 2 weeks) or gemcitabine (1000 mg/m 2, days 1, 8, and 15, every 4 weeks) as adjuvant therapy for 24 weeks. Main Outcomes and Measures: Primary end point was disease-free survival. Secondary end points included overall survival, metastasis-free survival, and cancer-specific survival. Prognostic factors for overall survival were determined. Results: Of the 493 patients, 216 (43.8%) were women, and the mean (SD) age was 62.0 (8.9) years. At a median of 69.7 months’ follow-up, 367 disease-free survival events were observed. In patients receiving chemotherapy with modified FOLFIRINOX vs gemcitabine, median disease-free survival was 21.4 months (95% CI, 17.5-26.7) vs 12.8 months (95% CI, 11.6-15.2) (hazard ratio [HR], 0.66; 95% CI, 0.54-0.82; P < .001) and 5-year disease-free survival was 26.1% vs 19.0%; median overall survival was 53.5 months (95% CI, 43.5-58.4) vs 35.5 months (95% CI, 30.1-40.3) (HR, 0.68; 95% CI, 0.54-0.85; P = .001), and 5-year overall survival was 43.2% vs 31.4%; median metastasis-free survival was 29.4 months (95% CI, 21.4-40.1) vs 17.7 months (95% CI, 14.0-21.2) (HR, 0.64; 95% CI, 0.52-0.80; P < .001); and median cancer-specific survival was 54.7 months (95% CI, 45.8-68.4) vs 36.3 months (95% CI, 30.5–43.9) (HR, 0.65; 95% CI, 0.51-0.82; P < .001). Multivariable analysis identified modified FOLFIRINOX, age, tumor grade, tumor staging, and larger-volume center as significant favorable prognostic factors for overall survival. Shorter relapse delay was an adverse prognostic factor. Conclusions and Relevance: The final 5-year results from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial indicate that adjuvant treatment with modified FOLFIRINOX yields significantly longer survival than gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Trial Registration: EudraCT: 2011-002026-52; ClinicalTrials.gov Identifier: NCT01526135
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Self-citationA Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O., & Bray, F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.005 · Cited by 2,478
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., et al. (2010) · JAMA · doi:10.1001/jama.2010.1275 · Cited by 1,397
Estimated Projection of US Cancer Incidence and Death to 2040
Rahib, L., Wehner, M. R., Matrisian, L. M., & Nead, K. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4708 · Cited by 1,339
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ducreux, M., Cuhna, A. S., Caramella, C., Hollebecque, A., Burtin, P., Goéré, D., Seufferlein, T., Haustermans, K., Van Laethem, J. L., Conroy, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv295 · Cited by 1,300
Self-citationUesaka, K., Boku, N., Fukutomi, A., Okamura, Y., Konishi, M., Matsumoto, I., Kaneoka, Y., Shimizu, Y., Nakamori, S., Sakamoto, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30583-9 · Cited by 1,115
Pourshams, A., Sepanlou, S. G., Ikuta, K. S., Bisignano, C., Safiri, S., Roshandel, G., Sharif, M., Khatibian, M., Fitzmaurice, C., Nixon, M. R., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30347-4 · Cited by 658
Research works printed but not linked: 3
- Ferlay, 2019, Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods., Int J Cancer, 144, 1941, 10.1002/ijc.v144.8 · doi:10.1002/ijc.v144.8
- Siegel, 2022, Cancer statistics, 2022., CA Cancer J Clin, 72, 7, 10.3322/caac.v72.1 · doi:10.3322/caac.v72.1
- Yu, 2021, Burden of pancreatic cancer along with attributable risk factors in Europe between 1990 and 2019, and projections until 2039., Int J Cancer, 149, 993, 10.1002/ijc.v149.5 · doi:10.1002/ijc.v149.5
Cited by
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O’Reilly, E. M., Hackert, T., Golan, T., Prager, G., Haustermans, K., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.009 · Cited by 610
Self-citationStoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 479
Jiang, J., Chao, W.-L., Culp, S., & Krishna, S. G. (2023) · Cancers · doi:10.3390/cancers15092410 · Cited by 38
Targeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis
Xing, Z., Ma, Y., Jiang, X., Qing, H., Wu, Y., Che, S., Gao, Z., Wang, K., Wang, T., He, Q., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02557-5 · Cited by 4
The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review
Pîntea, A.-I., Croitoru, A. E., Dinu-Pîrvu, C. E., & Dima, S. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1815366
“…the combination of gemcitabine and capecitabine, the former having yielded a median overall survival (OS) of 53.5 months in the PRODIGE 24 trial (Conroy et al., 2022), with a 5-year survival of 43.2%, while the latter a median OS of 29.5 months according to the ESPAC-4 trial (Palmer et al.,…”
Influential
Metadata
- Authors
- Conroy, T., Castan, F., Lopez, A., Turpin, A., Ben Abdelghani, M., Wei, A. C., Mitry, E., Biagi, J. J., Evesque, L., Artru, P., Lecomte, T., Assenat, E., Bauguion, L., Ychou, M., Bouché, O., Monard, L., Lambert, A., Hammel, P., Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group, Francois, E., Ramee, J.-F., Castanie, H., Pracht, M., Ghiringhelli, F., Maillard, E., Couffon, C., Volet, J., Bourgeois, V., Chauvenet, M., Blanc, J.-F., Péré-Vergé, D., De La Fouchardiere, C., Adenis, A., El Hajbi, F., Bennouna, J., Texereau, P., Faroux, R., Miglianico, L., Platini, C., Legoux, J.-L., Caroli-Bosc, F.-X., Bouhier-Leporrier, K., Gagnaire, A., Granger, V., Lebrun-Ly, V., Guimbaud, R., Touchefeu, Y., Gasmi, M., Di Fiore, F., Seitz, J. F., Etienne, P.-L., Ligeza Poisson, C., Rinaldi, Y., Baba-Hamed, N., Bachet, J. B., Aparicio, T., Chone, L., Guillet, M., Forestier, J., Terrebonne, E., Hebbar, M., Breysacher, G., Andre, T., Khemissa-Akouz, F., Hautefeuille, V., Guerin-Meyer, V., Hartwig, J., Becouarn, Y., Malka, D., Louvet, C., Raoul, J.-L., Cany, L., Juzina, B., Jouffroy, C., Gourgou, S., Rassouli, M., Chalchal, H., Renouf, D., Wong, R., Lemay, F., Aubin, F., Couture, F., Mc Whirter, E., Welch, S., Kavan, P., Findlay, B., Cripps, C., Cano, P., Ahmed, S., Harb, M., Pressnail, B., Dowden, S., & O'Callaghan, C.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2022-11-01
- Volume
- 8
- Issue
- 11
- Pages
- 1571
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W4294001741
- Cited by
- 344
- References
- 19
- FWCI
- 23.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2022.3829
- The paper
- Conroy, T., Castan, F., Lopez, A., Turpin, A., Ben Abdelghani, M., Wei, A. C., Mitry, E., Biagi, J. J., Evesque, L., Artru, P., Lecomte, T., Assenat, E., Bauguion, L., Ychou, M., Bouché, O., Monard, L., Lambert, A., Hammel, P., Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group, . . . O'Callaghan, C. (2022). Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2022.3829
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.